Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

Balance Sheet

Inspect the capital base behind the business.

Assets

$62.69M

FY 2025 · Annual

-43.6% YoY

Liabilities

$84.39M

FY 2025 · Annual

-17.4% YoY

Equity

-$21.69M

FY 2025 · Annual

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents103.76M84.23M70.61M66.4M28.08M
Short-term Investments16.08M17.26M21.85M14.37M6.22M
Net Receivables1.66M3.14M46.49M1.64M7.61M
Inventory00000
Other Current Assets11.81M27.88M00(4.28K)
Total Current Assets138.26M139.83M148.01M85.74M46.69M
Property, Plant & Equipment (Net)10.17M8.54M6.32M5.13M4.35M
Goodwill2K(41M)000
Intangible Assets44.19M42.55M416K00
Long-term Investments39.88M35.12M9.8M10.28M10.7M
Tax Assets5.03M8.57M9.01M00
Other Non-current Assets29.97M14.25M1.64M9.9M946.6K
Total Non-current Assets129.24M68.03M27.18M25.32M16M
Total Assets267.5M207.86M175.19M111.06M62.69M
Account Payables14.73M13.66M8.56M7.92M15.04M
Short-term Debt29.94M1.26M8.45M8.44M8.52M
Tax Payables7.46M5.98M7.02M6.96M0
Deferred Revenue12.5M6.56M5.87M616K2.82M
Other Current Liabilities21.91M19.02M7.82M7.65M9.97M
Total Current Liabilities79.89M41.34M39.64M32.98M36.63M
Long-term Debt11.49M38.93M30.61M22.18M13.67M
Deferred Tax Liabilities5.03M8.57M9.01M00
Deferred Revenue (Non-current)25.41M7.92M4.62M2.83M0
Other Non-current Liabilities36.23M55.74M39.07M44.13M33.99M
Total Non-current Liabilities80.17M112.37M83.65M69.24M47.75M
Total Liabilities160.06M153.71M132.29M102.23M84.39M
Common Stock3.98M4.01M4.04M4.19M4.69M
Retained Earnings(272.21M)(330.32M)(336.89M)(386.36M)(435.36M)
Accumulated OCI456K819K495K27K1.12M
Other Stockholders Equity(1K)0000
Minority Interest00000
Total Equity107.44M54.15M51.9M8.83M(21.69M)
Total Debt44.25M42.25M39.89M31M22.56M
Net Debt(59.51M)(41.97M)(30.71M)(35.4M)(5.52M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$28.1M
Short-term Investments$6.2M
Receivables$7.6M
Other Current$4.8M
Total Current Assets$46.7M
PP&E (Net)$4.4M
Long-term Investments$10.7M
Other Non-current$946.6K
Total Non-current Assets$16.0M
Total Assets$62.7M

Analysis

Selected assets total $62.7M for Latest. The largest visible component is Cash & Equivalents at $28.1M, about 44.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 12, 2026
6-K6-K filingNov 5, 2026
6-K6-K filingOct 27, 2026
6-K6-K filingOct 21, 2026
6-K6-K filingOct 20, 2026

How much cash does IPHA have?

Innate Pharma S.A. (IPHA) reported $28.08M in cash and equivalents in fiscal 2025.

How much debt does IPHA carry?

Innate Pharma S.A. (IPHA) reported $22.56M of total debt, with net debt of -$5.52M.